How do I treat patients with RRMM after failure of BCMA-targeted therapies?
Автор: Multiple Myeloma Hub
Загружено: 2024-10-17
Просмотров: 297
In this case, Dr Paul Richardson discusses strategies for treating RRMM after relapse with BCMA-targeted therapies, including CAR T-cell therapies, bispecific antibodies, and antibody−drug conjugates. He emphasizes the importance of alternative approaches, such as targeting non-BCMA antigens, using small molecule drugs, and combining antibodies with other agents. Dr Richardson highlights that while CAR T-cell therapies show remarkable results, they also present challenges like T-cell exhaustion, whereas salvage options remain more flexible with antibody−drug conjugates. He also notes ongoing research into next-generation therapies for more effective treatment.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
